Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Protagonist Therapeutics Inc (PTGX)

Protagonist Therapeutics Inc (PTGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Nike, Kura Sushi fall; Infinera, Protagonist Therapeutics rise, Friday, 6/28/2024 Associated Press - Fri Jun 28, 3:13PM CDT

Stocks that traded heavily or had substantial price changes on Friday: Nike, Kura Sushi fall; Infinera, Protagonist Therapeutics rise

FCX : 49.44 (+1.73%)
PTCT : 31.01 (+1.41%)
ACCD : 3.52 (-1.68%)
KRUS : 62.14 (-1.51%)
PTGX : 35.04 (+1.13%)
INFN : 6.10 (+0.16%)
Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress ACCESSWIRE - Tue May 14, 11:05AM CDT

NEWARK, CA / ACCESSWIRE / May 14, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that additional data from the rusfertide Phase 2 REVIVE open label...

PTGX : 35.04 (+1.13%)
Protagonist Therapeutics: Q1 Earnings Snapshot AP - Tue May 7, 3:23PM CDT

Protagonist Therapeutics: Q1 Earnings Snapshot

PTGX : 35.04 (+1.13%)
Protagonist Therapeutics: Q4 Earnings Snapshot AP - Tue Feb 27, 3:38PM CST

Protagonist Therapeutics: Q4 Earnings Snapshot

PTGX : 35.04 (+1.13%)
Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On Motley Fool - Thu Nov 16, 2023

Unsurprisingly, Johnson & Johnson's top investments are all in the healthcare sector.

NVS : 106.88 (+0.39%)
JNJ : 146.97 (+0.55%)
LEGN : 45.25 (+2.17%)
CVRX : 11.46 (-4.42%)
PTGX : 35.04 (+1.13%)
Protagonist Therapeutics: Q3 Earnings Snapshot AP - Thu Nov 2, 2023

Protagonist Therapeutics: Q3 Earnings Snapshot

PTGX : 35.04 (+1.13%)
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty FinancialNewsMedia - Fri Sep 22, 2023

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – September 22, 2023 – USA News Group  –  Despite the potential federal funding challenges due to the recent debt ceiling...

RY : 106.93 (+0.52%)
RY.TO : 145.65 (+0.17%)
ONCY : 0.9950 (+0.51%)
ONC.TO : 1.35 (-2.17%)
JAZZ : 107.40 (+0.63%)
ZYME : 8.51 (+1.19%)
AMGN : 316.98 (+1.45%)
PTGX : 35.04 (+1.13%)
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty PR Newswire - Fri Sep 22, 2023

/PRNewswire/ -- USA News Group - Despite the potential federal funding challenges due to the recent debt ceiling deal, optimism in the battle against cancer...

ONC.TO : 1.35 (-2.17%)
ONCY : 0.9950 (+0.51%)
ZYME : 8.51 (+1.19%)
JAZZ : 107.40 (+0.63%)
PTGX : 35.04 (+1.13%)
AMGN : 316.98 (+1.45%)
Pioneering Cancer Treatments Show Promising Progress Despite Fiscal Challenges BayStreet.ca - Wed Sep 20, 2023

USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal, optimism in the battle against cancer persists, thanks in large part to the audacious “Cancer...

RY : 106.93 (+0.52%)
RY.TO : 145.65 (+0.17%)
ONCY : 0.9950 (+0.51%)
ONC.TO : 1.35 (-2.17%)
JAZZ : 107.40 (+0.63%)
ZYME : 8.51 (+1.19%)
AMGN : 316.98 (+1.45%)
PTGX : 35.04 (+1.13%)
Protagonist Therapeutics: Q2 Earnings Snapshot AP - Thu Aug 3, 2023

Protagonist Therapeutics: Q2 Earnings Snapshot

PTGX : 35.04 (+1.13%)

Barchart Exclusives

Stock Market Forecast H2 2024: Will the 'AI Rally' Get a Reality Check? Barchart - 5 minutes ago
Defying all pessimism, the S&P 500 Index rose almost 15% in the first half of 2024 on the back of strength in AI stocks. Here's the stock market forecast for the back half of 2024, and the key events that investors should watch. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot